+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Middle East and Africa Multiple Sclerosis Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Drug Class, Route of Administration, and Distribution Channel

  • ID: 5359930
  • Report
  • May 2021
  • Region: Middle East, Africa
  • 128 pages
  • The Insight Partners
UP TO OFF
until Sep 30th 2021

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
The immunosuppressants segment by drug class is estimated to lead the market growth during the forecast period.



According to this study, the Middle East and Africa multiple sclerosis therapeutics market is expected to reach US$ 2,027.86 million by 2027 from US$ 1,319.08 million in 2019; it is estimated to grow at a CAGR of 5.7% from 2020 to 2027. The report highlights trends prevailing in the Middle East and Africa multiple sclerosis therapeutics market and the factors driving market along with those that act as hindrances.

The Middle East and Africa multiple sclerosis therapeutics market, by drug class, is segmented into immunosuppressant and immunomodulators. The immunomodulators segment held the largest share of the market in 2019, whereas the immunosuppressants segment is anticipated to register the highest CAGR in the market during the forecast period.

Multiple sclerosis (MS) is a chronic disease that affects the brain, spinal cord, and optic nerves. Studies show that there is an increase in the prevalence of multiple sclerosis across the Middle East and African countries. In recent years, various measures and efforts have been taken to create awareness and educate people regarding neurological diseases, which are facilitating patients to access suitable medications and treatments for such conditions. The Multiple Sclerosis Foundation and affiliated groups have initiated National MS Education and Awareness Month, which is observed in March since 2003 to increase awareness about the disease. The goal of this program is to promote an understanding of Multiple Sclerosis and help the patients in making educated decisions of its treatment. Also, the National MS Society created and launched the “MS Kills Connection > The report segments in Middle East and Africa Multiple Sclerosis Therapeutics Market as follows:

By Drug Class
  • Immunosuppressant
  • Immunomodulators
By Route of Administration
  • Injectable
  • Oral
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce
By Country
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of Middle East and Africa
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Biogen
  • F. HOFFMANN-LA ROCHE LTD
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
1. Introduction
1.1 Scope of the Study
1.2 The Publisher's Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East and Africa Multiple Sclerosis Therapeutics Market - By Drug Class
1.3.2 Middle East and Africa Multiple Sclerosis Therapeutics Market - By Route Of Administration
1.3.3 Middle East and Africa Multiple Sclerosis Therapeutics Market - By Distribution Channel
1.3.4 Middle East and Africa Multiple Sclerosis Therapeutics Market - By Country

2. Multiple Sclerosis Therapeutics Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East and Africa Multiple Sclerosis Therapeutics- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East and Africa (MEA) - PEST Analysis
4.2.2 Expert Opinions

5. Multiple Sclerosis Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Prevalence of Multiple Sclerosis (MS)
5.1.2 Rising Funding for Multiple Sclerosis Research
5.2 Market Restraints
5.2.1 High Cost of Multiple Sclerosis Treatment
5.3 Market Opportunities
5.3.1 Increasing Awareness About Multiple Sclerosis
5.4 Future Trends
5.4.1 Development and Launch of Innovative Products
5.5 Impact analysis

6. Multiple Sclerosis Therapeutics Market - Middle East and Africa Analysis
6.1 Middle East and Africa Multiple Sclerosis Therapeutics Market Revenue Forecast and Analysis

7. Multiple Sclerosis Therapeutics Market Analysis - By Drug Class
7.1 Overview
7.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
7.3 Immunosuppressant
7.3.1 Overview
7.3.2 Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
7.4 Immunomodulators
7.4.1 Overview
7.4.2 Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

8. Multiple Sclerosis Therapeutics Market Analysis - By Route of Administration
8.1 Overview
8.2 Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
8.3 Injectable
8.3.1 Overview
8.3.2 Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
8.4 Oral
8.4.1 Overview
8.4.2 Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

9. Multiple Sclerosis Therapeutics Market Analysis - By Distribution Channel
9.1 Overview
9.2 Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.4 Retail Pharmacies
9.4.1 Overview
9.4.2 Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
9.5 E-Commerce
9.5.1 Overview
9.5.2 E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)

10. Multiple Sclerosis Therapeutics Market Analysis and Forecast To 2027 - Middle East and Africa Analysis
10.1 Middle East and Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027
10.1.1 Overview
10.1.2 Middle East and Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)
10.1.3 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.1 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.3.2 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.3.3 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.3.4 Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.4 South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027
10.1.4.1 South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.4.2 South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.4.3 South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.4.4 South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel US$ Mn)
10.1.5 UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027
10.1.5.1 UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
10.1.5.2 UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
10.1.5.3 UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Route of Administration (US$ Mn)
10.1.5.4 UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts To 2027, By Distribution Channel (US$ Mn)
10.1.5.5 Rest of Middle East and Africa: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (USD Million)

11. Impact of COVID-19 Pandemic on Middle East and Africa Multiple Sclerosis Therapeutics Market
11.1 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

12. Industry Landscape
12.1 Overview
12.2 Organic Developments
12.2.1 Overview
12.3 Inorganic Developments
12.3.1 Overview

13. Company Profiles
13.1 Merck & Co., Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Novartis AG
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Sanofi
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bristol-Myers Squibb Company
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 F. HOFFMANN-LA ROCHE LTD.
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Biogen
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

14. Appendix
14.1 About the Publisher
14.2 Glossary of Terms

List of Tables
Table 1. Saudi Arabia Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 2. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 3. Saudi Arabia Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 4. South Africa Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 5. South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 6. South Africa Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 7. UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Drug Class (US$ Mn)
Table 8. UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Route of Administration (US$ Mn)
Table 9. UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027, By Distribution Channel (US$ Mn)
Table 13. Organic Developments Done By Companies
Table 14. Inorganic Developments Done By Companies
Table 15. Glossary of Terms, Multiple sclerosis therapeutics Market

List of Figures
Figure 1. Multiple Sclerosis Therapeutics Market Segmentation
Figure 2. Multiple Sclerosis Therapeutics Market Segmentation, By Country
Figure 3. Multiple Sclerosis Therapeutics Market Overview
Figure 4. Immunomodulators Segment by Drug Class Held the Larger Share of Multiple Sclerosis Therapeutics Market
Figure 5. Middle East and Africa Multiple Sclerosis Therapeutics Market - Leading Country Markets (US$ Million)
Figure 6. Middle East and Africa (MEA) PEST Analysis
Figure 7. Multiple Sclerosis Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. Middle East and Africa Multiple Sclerosis Therapeutics Market - Revenue Forecast and Analysis - 2019- 2027
Figure 9. Multiple Sclerosis Therapeutics Market Revenue Share, by Drug Class (2019 and 2027)
Figure 10. Immunosuppressant: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 11. Immunomodulators: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 12. Multiple Sclerosis Therapeutics Market Revenue Share, by Route of Administration (2019 and 2027)
Figure 13. Injectable: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 14. Oral: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 15. Multiple Sclerosis Therapeutics Market Share, by Distribution Channel, 2019 and 2027
Figure 16. Hospital Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 17. Retail Pharmacies: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 18. E-Commerce: Multiple Sclerosis Therapeutics Market - Revenue and Forecast to 2027 (US$ Million)
Figure 19. Middle East and Africa Multiple Sclerosis Therapeutics Market Share Overview, By Country (2019)
Figure 20. Middle East and Africa Multiple Sclerosis Therapeutics Market Share, By Country (2019 & 2027) (%)
Figure 21. Saudi Arabia Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. South Africa Multiple Sclerosis Therapeutic Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 23. UAE Multiple Sclerosis Therapeutics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Impact of COVID-19 Pandemic in Middle East and Africa Market
Note: Product cover images may vary from those shown
  • Merck & Co., Inc.
  • Novartis AG
  • Bayer AG
  • Sanofi
  • Bristol-Myers Squibb Company
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • F. HOFFMANN-LA ROCHE LTD
  • Biogen
Note: Product cover images may vary from those shown
Adroll
adroll